相关实验视频

Updated: Jan 9, 2026

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

MET过度表达与高级非小细胞肺癌中优越的免疫疗法益处有关

Hui Li^1,2, Lingzhi Hong¹, Pedro Rocha^3,4

¹Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

|December 11, 2025

概括

过度表达MET在晚期非小细胞肺癌 (NSCLC) 中很常见. 这项研究发现,MET过度表达预测了接受免疫检查点抑制剂 (ICI) 的NSCLC患者的更好的生存结果.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
免疫治疗是一种免疫疗法.

背景情况:

在非小细胞肺癌 (NSCLC) 中,MET过度表达是常见的.
在NSCLC中,MET过度表达和免疫检查点抑制剂 (ICI) 疗效之间的联系尚不清楚.
了解ICI治疗的预测生物标志物对于优化NSCLC治疗至关重要.

研究的目的:

调查MET过度表达与IV期NSCLC患者的生存结果之间的关联,这些患者接受ICI治疗.
确定MET表达水平是否可以作为ICI疗效的预测生物标志物.
探索MET过度表达,PD-L1表达和临床结果之间的关系.

主要方法:

对279名IV期NSCLC患者的回顾性分析,这些患者接受了ICI治疗.
使用免疫组织化学 (IHC) 评估MET表达,过度表达被定义为2+或3+.
使用后勤回归分析的临床病理特征.
使用Kaplan-Meier分析和Cox比例危险模型评估的整体存活率 (OS) 和无进展存活率 (PFS),并使用Akaike信息标准 (AIC) 改进模型.

主要成果:

在78.9%的患者中存在MET过度表达.
腺癌组织学和PD-L1表达独立地与MET过度表达相关.
患有MET过度表达的患者表现出明显更好的OS和PFS.
在多变量分析和对转移性负担进行调整后,MET过度表达仍然是OS和PFS的显著独立预后因素.

结论:

通过IHC检测到的MET过度表达与接受ICI的晚期NSCLC患者的生存率改善有关,无论PD-L1状态如何.
在NSCLC中,MET表达显示出作为ICI反应的预测生物标志物的潜力.
将MET向疗法与ICI结合起来,对于MET过度表达的NSCLC患者来说可能是一个有前途的策略.

关键词:

在MET中,过度表达过度.在PD-L1中.免疫检查点抑制剂免疫检查点抑制剂非小细胞肺癌的肺癌.

更多相关视频

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...